Tvardi Therapeutics

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of STAT3 inhibitors for cancer and inflammatory diseases. The company's lead candidate TTI-101 is an oral small-molecule STAT3 inhibitor; TTI-109 is a phosphate prodrug of TTI-101 designed to improve oral bioavailability while preserving target engagement. The Phase 1 study of TTI-109 announced July 7, 2026 confirmed rapid prodrug conversion to TTI-101 within two hours, dose-proportional pharmacokinetics with plasma levels above the STAT3 IC50, and reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh, and B cell subsets in an exploratory pharmacodynamic analysis. Planned Phase 2 initiation in hepatocellular carcinoma and other STAT3-driven indications is the next value-driving event. Tvardi is headquartered in Houston, Texas and trades on the Nasdaq Capital Market under the symbol TVRD.